Cargando…
Repurposing Probenecid for the Treatment of Heart Failure (Re-Prosper-HF): a study protocol for a randomized placebo-controlled clinical trial
BACKGROUND: Improving contractility in heart failure with reduced ejection fraction (HFrEF) has resurfaced as a potential treatment goal. Inotropic therapy is now better understood through its underlying mechanism as opposed to the observed effect of increasing contractility. Calcitropes are a subgr...
Autores principales: | Rubinstein, Jack, Robbins, Nathan, Evans, Karen, Foster, Gabrielle, Mcconeghy, Kevin, Onadeko, Toluwalope, Bunke, Julie, Parent, Melanie, Luo, Xi, Joseph, Jacob, Wu, Wen-Chih |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8991789/ https://www.ncbi.nlm.nih.gov/pubmed/35392963 http://dx.doi.org/10.1186/s13063-022-06214-y |
Ejemplares similares
-
Probenecid treatment improves outcomes in a novel mouse model of peripartum cardiomyopathy
por: Onusko, Evan, et al.
Publicado: (2020) -
Probenecid: An Oral Inotrope for End-Stage Heart Failure in a Case With Myotonic Dystrophy
por: Klein, Evan C., et al.
Publicado: (2019) -
Pancreatic resection with perioperative drug repurposing of propranolol and etodolac: trial protocol of the phase-II randomised placebo controlled PROSPER trial
por: Hüttner, Felix J, et al.
Publicado: (2020) -
Probenecid Improves Cardiac Function in Patients With Heart Failure With Reduced Ejection Fraction In Vivo and Cardiomyocyte Calcium Sensitivity In Vitro
por: Robbins, Nathan, et al.
Publicado: (2018) -
Repurposing Probenecid to Inhibit SARS-CoV-2, Influenza Virus, and Respiratory Syncytial Virus (RSV) Replication
por: Tripp, Ralph A., et al.
Publicado: (2022)